Global Retirement Partners’s Scinai Immunotherapeutics SCNI Stock Holding History

Global Retirement Partners’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5	Closed	-$14	–	3625
2024 Q2	$14	Hold	5	–	–	﹤0.01%	3527
2024 Q1	$26	Hold	5	–	–	﹤0.01%	3350
2023 Q4	$29	Hold	5	–	–	﹤0.01%	3316
2023 Q3	$38	Hold	5	–	–	﹤0.01%	3208
2023 Q2	$71	Hold	5	–	–	﹤0.01%	3147
2023 Q1	$95	Hold	5	–	–	﹤0.01%	3127
2022 Q4	$148	Hold	5	–	–	﹤0.01%	2954
2022 Q3	$0	Hold	5	–	–	﹤0.01%	2938
2022 Q2	$1K	Hold	5	–	–	﹤0.01%	2548
2022 Q1	$1K	Buy	+5	New	+$726	﹤0.01%	2507
2021 Q4	–	Sell	-5	Closed	-$1K	–	1506
2021 Q3	$1K	Hold	5	–	–	﹤0.01%	1929
2021 Q2	$1K	Hold	5	–	–	﹤0.01%	1825
2021 Q1	$2K	Hold	5	–	–	﹤0.01%	1666
2020 Q4	$1K	Buy	+5	New	+$6.05K	﹤0.01%	1695

Other funds holding SCNI

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Global Retirement Partners's SCNI Position: Q3 2024 in Review

Global Retirement Partners sold out of Scinai Immunotherapeutics (SCNI) in Q3 2024, closing a stake of 5 shares — an estimated $14 sold.

Global Retirement Partners first reported a position in SCNI in Q4 2020 and held it in 14 quarters. The position peaked at $2K in Q1 2021. 5 funds tracked by Wall St. Rank hold SCNI as of Q3 2024.

Global Retirement Partners reported no remaining Scinai Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
Global Retirement Partners sold 5 Scinai Immunotherapeutics shares in Q3 2024, an estimated $14.
Global Retirement Partners first reported a position in Scinai Immunotherapeutics in Q4 2020 and held it in 14 quarters.
Global Retirement Partners's Scinai Immunotherapeutics position peaked at $2K in Q1 2021.
5 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2024.

Based on Global Retirement Partners's 13F filing for Q3 2024, filed 16 Oct 2024.